QuidelOrtho (QDEL) Stock Forecast, Price Target & Predictions
QDEL Stock Forecast
QuidelOrtho stock forecast is as follows: an average price target of $93.40 (represents a 142.09% upside from QDEL’s last price of $38.58) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
QDEL Price Target
The average price target for QuidelOrtho (QDEL) is $93.40 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $125.00 to $50.00. This represents a potential 142.09% upside from QDEL's last price of $38.58.
QDEL Analyst Ratings
According to 5 Wall Street analysts, QuidelOrtho's rating consensus is 'Buy'. The analyst rating breakdown for QDEL stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
QuidelOrtho Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 19, 2024 | Lu Li | UBS | $50.00 | $46.23 | 8.15% | 29.60% |
| Sep 05, 2024 | Bill Bonello | Craig-Hallum | $57.00 | $42.93 | 32.77% | 47.74% |
| Aug 15, 2023 | Andrew Cooper | Raymond James | $110.00 | $74.47 | 47.71% | 185.12% |
| Dec 12, 2022 | - | Citigroup | $125.00 | $92.30 | 35.43% | 224.00% |
| Dec 07, 2022 | - | RBC Capital | $125.00 | $92.19 | 35.59% | 224.00% |
| Oct 14, 2022 | Elizabeth Garcia | UBS | $86.00 | $76.38 | 12.59% | 122.91% |
The latest QuidelOrtho stock forecast, released on Sep 19, 2024 by Lu Li from UBS, set a price target of $50.00, which represents a 8.15% increase from the stock price at the time of the forecast ($46.23), and a 29.60% increase from QDEL last price ($38.58).
QuidelOrtho Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 2 | 2 |
| Avg Price Target | - | $53.50 | $53.50 |
| Last Closing Price | $38.58 | $38.58 | $38.58 |
| Upside/Downside | -100.00% | 38.67% | 38.67% |
In the current month, the average price target of QuidelOrtho stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to QuidelOrtho's last price of $38.58. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 19, 2024 | UBS | Buy | Buy | Hold |
| Sep 19, 2024 | RBC Capital | Underperform | Underperform | Hold |
| Sep 19, 2024 | UBS | - | Neutral | Upgrade |
| Sep 05, 2024 | Craig-Hallum | - | Buy | Upgrade |
| May 09, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Apr 02, 2024 | William Blair | Market Perform | Market Perform | Hold |
| Apr 02, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Feb 14, 2024 | Raymond James | Strong Buy | Outperform | Downgrade |
| Feb 14, 2024 | RBC Capital | Outperform | Outperform | Hold |
| Feb 14, 2024 | William Blair | - | Market Perform | Downgrade |
QuidelOrtho's last stock rating was published by UBS on Sep 19, 2024. The company gave QDEL a "Buy" rating, the same as its previous rate.
QuidelOrtho Financial Forecast
QuidelOrtho Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $742.60M | $744.00M | $665.10M | $846.10M | - | $783.80M | $613.40M | $1.00B | $636.87M | $509.74M | $176.61M | $375.34M | $809.20M | $476.06M | $201.75M | $174.65M | $152.18M | $126.49M |
| Avg Forecast | $769.96M | $696.19M | $648.39M | $718.94M | $727.98M | $694.01M | $640.84M | $707.13M | $700.64M | $642.16M | $613.51M | $693.24M | $796.91M | $691.90M | $615.11M | $778.03M | $770.57M | $719.60M | $768.24M | $891.08M | $540.90M | $376.90M | $174.38M | $400.76M | $810.29M | $450.41M | $189.79M | $157.49M | $143.92M | $125.52M |
| High Forecast | $781.96M | $707.04M | $658.49M | $730.14M | $739.32M | $704.82M | $650.83M | $719.86M | $704.31M | $645.58M | $613.51M | $693.24M | $821.63M | $709.40M | $624.69M | $790.15M | $782.58M | $719.60M | $768.24M | $891.08M | $540.90M | $376.90M | $174.38M | $400.76M | $810.29M | $450.41M | $189.79M | $157.49M | $143.92M | $125.52M |
| Low Forecast | $757.18M | $684.63M | $637.62M | $707.01M | $715.89M | $682.49M | $630.21M | $694.27M | $695.92M | $638.75M | $613.51M | $693.24M | $780.08M | $640.37M | $604.89M | $765.11M | $757.78M | $719.60M | $768.24M | $891.08M | $540.90M | $376.90M | $174.38M | $400.76M | $810.29M | $450.41M | $189.79M | $157.49M | $143.92M | $125.52M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 3 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 8 | 7 | 6 | 5 | 5 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.93% | 1.08% | 1.08% | 1.09% | - | 1.09% | 0.80% | 1.12% | 1.18% | 1.35% | 1.01% | 0.94% | 1.00% | 1.06% | 1.06% | 1.11% | 1.06% | 1.01% |
QuidelOrtho's average Quarter revenue forecast for Mar 24 based on 2 analysts is $693.24M, with a low forecast of $693.24M, and a high forecast of $693.24M. QDEL's average Quarter revenue forecast represents a -6.65% decrease compared to the company's last Quarter revenue of $742.60M (Dec 23).
QuidelOrtho EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 3 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 8 | 7 | 6 | 5 | 5 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $40.10M | $26.30M | $47.70M | $177.20M | - | $137.90M | $178.40M | $640.48M | $384.53M | $281.84M | $24.33M | $237.62M | $617.60M | $308.35M | $84.53M | $53.54M | $37.61M | $25.14M |
| Avg Forecast | $308.67M | $279.10M | $259.93M | $288.22M | $291.84M | $278.22M | $256.91M | $283.48M | $280.88M | $257.44M | $245.95M | $457.53M | $319.47M | $277.38M | $246.59M | $489.34M | $199.87M | $280.30M | $299.25M | $523.36M | $210.69M | $146.81M | $67.93M | $253.49M | $315.62M | $175.45M | $73.93M | $45.89M | $56.06M | $48.89M |
| High Forecast | $313.48M | $283.44M | $263.98M | $292.71M | $296.39M | $282.56M | $260.91M | $288.58M | $282.35M | $258.81M | $245.95M | $549.04M | $329.38M | $284.39M | $250.43M | $587.21M | $239.85M | $280.30M | $299.25M | $628.03M | $210.69M | $146.81M | $67.93M | $304.19M | $315.62M | $175.45M | $73.93M | $55.07M | $56.06M | $48.89M |
| Low Forecast | $303.55M | $274.46M | $255.62M | $283.43M | $287.00M | $273.60M | $252.64M | $278.33M | $278.99M | $256.07M | $245.95M | $366.03M | $312.73M | $256.72M | $242.50M | $391.47M | $159.90M | $280.30M | $299.25M | $418.69M | $210.69M | $146.81M | $67.93M | $202.79M | $315.62M | $175.45M | $73.93M | $36.71M | $56.06M | $48.89M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.13% | 0.09% | 0.19% | 0.36% | - | 0.49% | 0.60% | 1.22% | 1.83% | 1.92% | 0.36% | 0.94% | 1.96% | 1.76% | 1.14% | 1.17% | 0.67% | 0.51% |
2 analysts predict QDEL's average Quarter EBITDA for Mar 24 to be $457.53M, with a high of $549.04M and a low of $366.03M. This is 1040.98% upper than QuidelOrtho's previous annual EBITDA (Dec 23) of $40.10M.
QuidelOrtho Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 3 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 8 | 7 | 6 | 5 | 5 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $7.00M | $-12.70M | $-53.20M | $48.80M | - | $19.20M | $19.30M | $479.94M | $291.32M | $215.75M | $19.07M | $178.08M | $470.13M | $232.27M | $67.65M | $40.24M | $30.63M | $16.18M |
| Avg Forecast | $79.44M | $45.91M | $19.66M | $57.33M | $70.04M | $47.58M | $10.58M | $46.93M | $43.91M | $18.24M | $-15.69M | $344.48M | $137.18M | $40.21M | $18.76M | $368.43M | $148.87M | $49.72M | $180.06M | $394.04M | $376.27M | $236.46M | $80.74M | $190.56M | $666.71M | $309.99M | $63.77M | $28.80M | $40.93M | $26.03M |
| High Forecast | $81.05M | $46.83M | $20.06M | $58.50M | $71.46M | $48.54M | $10.79M | $48.38M | $47.19M | $18.61M | $-15.35M | $413.38M | $150.09M | $73.73M | $19.14M | $442.12M | $178.64M | $49.72M | $180.06M | $472.85M | $376.27M | $236.46M | $80.74M | $228.67M | $666.71M | $309.99M | $63.77M | $34.56M | $40.93M | $26.03M |
| Low Forecast | $77.72M | $44.91M | $19.24M | $56.10M | $68.53M | $46.55M | $10.35M | $44.51M | $41.03M | $17.85M | $-16.01M | $275.59M | $127.00M | $26.81M | $18.35M | $294.74M | $119.09M | $49.72M | $180.06M | $315.23M | $376.27M | $236.46M | $80.74M | $152.45M | $666.71M | $309.99M | $63.77M | $23.04M | $40.93M | $26.03M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | -0.32% | -2.84% | 0.13% | - | 0.39% | 0.11% | 1.22% | 0.77% | 0.91% | 0.24% | 0.93% | 0.71% | 0.75% | 1.06% | 1.40% | 0.75% | 0.62% |
QuidelOrtho's average Quarter net income forecast for Mar 24 is $344.48M, with a range of $275.59M to $413.38M. QDEL's average Quarter net income forecast represents a 4821.17% increase compared to the company's last Quarter net income of $7.00M (Dec 23).
QuidelOrtho SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 3 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 8 | 7 | 6 | 5 | 5 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $187.60M | $194.10M | $179.10M | $202.40M | - | $204.20M | $118.40M | $89.90M | $78.70M | $67.89M | $59.24M | $53.74M | $58.40M | $53.82M | $43.25M | $45.07M | $42.30M | $38.74M |
| Avg Forecast | $157.78M | $142.66M | $132.87M | $147.32M | $149.18M | $142.22M | $131.32M | $144.90M | $143.57M | $131.59M | $125.72M | $64.52M | $163.30M | $141.78M | $126.05M | $69.01M | $40.22M | $147.51M | $157.48M | $73.81M | $110.88M | $77.26M | $35.75M | $57.51M | $166.10M | $92.33M | $38.90M | $54.26M | $29.50M | $25.73M |
| High Forecast | $160.24M | $144.89M | $134.94M | $149.62M | $151.50M | $144.43M | $133.37M | $147.51M | $144.33M | $132.29M | $125.72M | $77.43M | $168.37M | $145.37M | $128.01M | $82.81M | $48.26M | $147.51M | $157.48M | $88.57M | $110.88M | $77.26M | $35.75M | $69.01M | $166.10M | $92.33M | $38.90M | $65.12M | $29.50M | $25.73M |
| Low Forecast | $155.16M | $140.29M | $130.66M | $144.88M | $146.70M | $139.85M | $129.14M | $142.27M | $142.61M | $130.89M | $125.72M | $51.62M | $159.85M | $131.22M | $123.95M | $55.21M | $32.17M | $147.51M | $157.48M | $59.05M | $110.88M | $77.26M | $35.75M | $46.00M | $166.10M | $92.33M | $38.90M | $43.41M | $29.50M | $25.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.15% | 1.37% | 1.42% | 2.93% | - | 1.38% | 0.75% | 1.22% | 0.71% | 0.88% | 1.66% | 0.93% | 0.35% | 0.58% | 1.11% | 0.83% | 1.43% | 1.51% |
QuidelOrtho's average Quarter SG&A projection for Mar 24 is $64.52M, based on 2 Wall Street analysts, with a range of $51.62M to $77.43M. The forecast indicates a -65.61% fall compared to QDEL last annual SG&A of $187.60M (Dec 23).
QuidelOrtho EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 3 | 2 | 2 | 4 | 4 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 8 | 7 | 6 | 5 | 5 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $0.10 | $-0.19 | $-0.80 | $0.73 | - | $0.29 | $0.37 | $11.46 | $6.98 | $5.17 | $0.46 | $4.19 | $11.14 | $5.52 | $1.61 | $0.96 | $0.73 | $0.39 |
| Avg Forecast | $1.18 | $0.68 | $0.29 | $0.85 | $1.04 | $0.71 | $0.16 | $0.70 | $0.65 | $0.27 | $-0.23 | $0.39 | $2.04 | $0.60 | $0.28 | $1.49 | $1.43 | $0.74 | $2.68 | $9.89 | $5.61 | $3.52 | $1.20 | $4.50 | $9.94 | $4.62 | $0.95 | $0.75 | $0.61 | $0.39 |
| High Forecast | $1.20 | $0.70 | $0.30 | $0.87 | $1.06 | $0.72 | $0.16 | $0.72 | $0.70 | $0.28 | $-0.23 | $0.39 | $2.23 | $1.10 | $0.28 | $1.52 | $1.46 | $0.74 | $2.68 | $9.89 | $5.61 | $3.52 | $1.20 | $4.50 | $9.94 | $4.62 | $0.95 | $0.75 | $0.61 | $0.39 |
| Low Forecast | $1.15 | $0.67 | $0.29 | $0.83 | $1.02 | $0.69 | $0.15 | $0.66 | $0.61 | $0.27 | $-0.24 | $0.39 | $1.89 | $0.40 | $0.27 | $1.46 | $1.40 | $0.74 | $2.68 | $9.89 | $5.61 | $3.52 | $1.20 | $4.50 | $9.94 | $4.62 | $0.95 | $0.75 | $0.61 | $0.39 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.05% | -0.32% | -2.87% | 0.49% | - | 0.39% | 0.14% | 1.16% | 1.24% | 1.47% | 0.38% | 0.93% | 1.12% | 1.19% | 1.69% | 1.27% | 1.20% | 1.01% |
According to 2 Wall Street analysts, QuidelOrtho's projected average Quarter EPS for Mar 24 is $0.39, with a low estimate of $0.39 and a high estimate of $0.39. This represents a 290.14% increase compared to QDEL previous annual EPS of $0.10 (Dec 23).
QuidelOrtho Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| TNDM | Tandem Diabetes Care | $27.87 | $79.05 | 183.64% | Buy |
| QDEL | QuidelOrtho | $38.58 | $93.40 | 142.09% | Buy |
| LUNG | Pulmonx | $6.00 | $11.93 | 98.83% | Buy |
| KIDS | OrthoPediatrics | $24.32 | $39.60 | 62.83% | Buy |
| SIBN | SI-BONE | $12.32 | $20.00 | 62.34% | Buy |
| BRKR | Bruker | $48.25 | $73.75 | 52.85% | Buy |
| NPCE | NeuroPace | $9.18 | $12.88 | 40.31% | Buy |
| LIVN | LivaNova | $51.36 | $70.50 | 37.27% | Buy |
| INSP | Inspire Medical Systems | $176.05 | $239.55 | 36.07% | Buy |
| CNMD | CONMED | $71.75 | $96.00 | 33.80% | Buy |
| NARI | Inari Medical | $50.97 | $66.11 | 29.70% | Buy |
| STE | STERIS | $212.00 | $256.67 | 21.07% | Buy |
| DXCM | DexCom | $74.88 | $81.36 | 8.65% | Buy |
| PODD | Insulet | $261.99 | $274.00 | 4.58% | Buy |
| MASI | Masimo | $163.50 | $161.83 | -1.02% | Buy |
| PEN | Penumbra | $237.11 | $224.85 | -5.17% | Buy |
| GKOS | Glaukos | $144.21 | $123.44 | -14.40% | Buy |
| SWAV | ShockWave Medical | $334.75 | $258.17 | -22.88% | Hold |